Non-Hodgkin lymphoma Posts - Page 2 of 43 on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

How safe and effective is epcoritamab for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma?

Posted by on Nov 21, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients.  Some background B-NHL is a type of...

Read More

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Posted by on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL).   This study concluded that this treatment can be effective in these patients.   Some background Radiotherapy (RT) is an important treatment in managing patients...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.  Some background Treatments for...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More

Which type of CAR T cell therapy is best for patients with relapsed or refractory large B cell lymphoma?

Which type of CAR T cell therapy is best for patients with relapsed or refractory large B cell lymphoma?

Posted by on Oct 26, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of lisocabtagene maraleucel (liso-cel; Breyanzi) and axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed or refractory (r/r) large B cell lymphoma (LBCL). The study found that both treatments were similarly effective but liso-cel was better tolerated in these...

Read More

Reviewing the chemotherapy-free treatment of follicular and marginal zone lymphoma

Reviewing the chemotherapy-free treatment of follicular and marginal zone lymphoma

Posted by on Oct 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The review aimed to assess chemotherapy-free treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL).   Some background Standard therapy for slow-growing non-Hodgkin lymphoma (NHL) such as FL and MZL involves immunochemotherapy (ICT). ICT combines immunotherapy and chemotherapy treatments. However, many patients...

Read More

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Posted by on Oct 16, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The...

Read More

Which type of stem cell transplant is best for patients with T-cell lymphoma?

Which type of stem cell transplant is best for patients with T-cell lymphoma?

Posted by on Sep 26, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use of two types of stem cell transplant (SCT) in the treatment of T-cell lymphoma.  It found that both haploidentical and umbilical cord blood SCT were good options for these patients.  Some background T-cell lymphoma is a cancer affecting a certain type of blood cell called T-cells. T-cells are...

Read More

Can FDG-PET/CT help predict T-cell therapy outcomes for patients with B-cell NHL?

Can FDG-PET/CT help predict T-cell therapy outcomes for patients with B-cell NHL?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the role of PET/CT scanning in the treatment of patients with recurrent or hard-to-treat B-cell non-Hodgkin’s lymphoma (NHL) after T-cell therapy. This study found that PET/CT scanning helped predict the effectiveness and side effects of treatment for these patients. Some background Chemoimmunotherapy...

Read More

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Do patients with B-cell lymphoma respond properly to the Pfizer BioNTech COVID-19 vaccine?

Posted by on Sep 12, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the use and response of the Pfizer BioNTech COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma (NHL). It found that patients with NHL undergoing treatment with rituximab (Rituxan)/obinutuzumab (Gazyva) had a poorer immune response to this vaccine, compared to patients without...

Read More